Fig. 2
Assessment of body weight, fluid intake and symptoms following AOM/DSS treatment. (A) Body weight curves for AOM/DSS (++) and control (−) treated B6 and A/J mice, presented as mean. DSS/H2O treatment periods are highlighted with grey background. Statistical differences were determined over the timepoints where data was collected for all groups, using repeated-measures two-way ANOVA with Greenhouse-Geisser correction and Tukey’s multiple comparisons tests (A/J++ vs B6++ *p ≤ 0.05; B6++ vs B6- #p ≤ 0.05, ##p ≤ 0.01). n = 5 in each group. (B) DSS intake for AOM/DSS (++) treated B6 and A/J mice. Bars represent estimated average intake per animal, calculated based on drinking bottle volumes for each cage, presented as mean (SD) of mean intake for the whole treatment regimen. (C) Number of individuals in the AOM/DSS (++) treated B6 (left) and A/J (right) mice exhibiting clinical symptoms of abnormal appearance, rectal bleeding (including blood in feces) and/or rectal prolapse at different timepoints during the trial. DSS treatment periods are highlighted with grey background